ChromaDex Corporation Reports 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St set for higher open but weekly losses loom
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
ChromaDex (CDXC) Misses Q4 EPS by 1c
March 10, 2021 4:26 PM ESTChromaDex (NASDAQ: CDXC) reported Q4 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $15.4 million versus the consensus estimate of $15.36 million.
Fourth Quarter 2020 and Recent Highlights
Total net sales of $15.4 million, up 18% from $13.1 million in the year ago quarter.Tru Niagen® net sales of $12.3 million, a 21% increase from the year ago quarter.Gross margin of 61.0%, a 400 basis point increase from the year ago quarter.Net loss was ($6.1) million or ($0.10) per share,... More